Tetrapyrroles and derivatives
Abcam (R,S)-CPP, NMDA antagonist, 50MG
MW 252.2 Da. Potent, competitive NMDA antagonist. See separate isomer (ab120159). Also available in simple stock solutions (ab146720) - add 1 ml of water to get an exact, ready-to-use concentration.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 206553 hydrochloride, 5-HT2B and 5-HT2C receptor antagonist, 10MG
MW 292.33 Da, Purity >99%. Potent and selective 5-HT2B and 5-HT2C serotonin receptor antagonist (pKi values are 7.92 (5-HT2C), 5.78 (5-HT2A), 7.65 (5-HT2B), 1A), 1D), 1E) and 1F). Centrally active following oral administration.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Geldanamycin-FITC, fluorescent labelled HSP90 inhibitor, 1MG
MW 1034.2 g/mol, Purity >98%. Potent fluorescent labelled-HSP90 inhibitor for in vitro and in vivo use. Geldanamycin from Streptomyces hygroscopicus.
The product is subject to the following: Abcam Restricted Use Statement
Abcam A 943931 dihydrochloride, H4 receptor antagonist, 10MG
MW 368.3 Da, Purity >99%. Potent and selective H4 receptor antagonist (pKi = 7-8). Shows anti-inflammatory and analgesic effects *in vivo.* Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam QVD-OPh, caspase inhibitor, 5MG
MW 513.5 Da, Purity >95%. QVD-OPh, caspase inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Latrunculin A (LAT-A), Actin polymerization inhibitor, 100UG
MW 421.6 Da, Purity >95%. Actin polymerization inhibitor. Potent antiproliferative agent. Stabilizes monomeric G-actin. Shows greater potency than Latrunculin B (ab144291). Binds actin monomers near the nucleotide binding cleft with 1:1 stoichiometry. Inhibits growth of cancer cell lines (IC₅₀ values are 142, 142, 142, 166 and 95 nM for A549, H522-T1, HT-29, U-937 and MDA-MB-43 cells respectively). Shows convulsant effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Tetrahydrouridine, cytidine deaminase inhibitor, 25MG
MW 248.23 Da, Purity >80%. Competitive cytidine deaminase inhibitor (IC₅₀= 152 μM). Modulates antiproliferative effects. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AT x -II, NaV channel activator, 50UG
MW 4941 Da, Purity >95%. ATX-II, NaV channel activator. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam IBM x , Non-specific cAMP and cGMP inhibitor, 1G
MW 222.24 Da, Purity >98%. Non-specific cAMP and cGMP inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam A 769662, AMP-activated protein kinase activator, 50MG
MW 360.4 Da, Purity >99%. Potent, reversible activator of AMP-activated protein kinase (AMPK) (EC₅₀ = 0.8 μM). Directly activates native rat AMPK by mimicking the effects of AMP - it activates AMPK both allosterically and by inhibiting dephosphorylation of AMPK. Shown to inhibit Na+-K+-ATPase at higher concentrations (IC₅₀ = 57 μM) . Inhibits differentiation of adipocytes.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 203580, p38 MAPK inhibitor, 10MG
MW 377.4 Da, Purity >99%. SB 203580, p38 MAPK inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Necrostatin-1, necroptosis inhibitor, 5MG
MW 259.33 Da, Purity >99%. Potent, specific necroptosis inhibitor (EC₅₀ = 490 nM). Selective allosteric inhibitor of death domain receptor-associated adaptor kinase RIP1 in vitro (EC₅₀ = 182 nM). Caspase independent, programmed necrosis pathway.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Dihydrokainic acid, EAAT2 (GLT-1) inhibitor, 50MG
MW 215.25 Da. Selective, non-transportable inhibitor of glutamate transporter EAAT2 (GLT-1) (Ki = 23 μM). 130-fold selective over EAAT1 and EAAT3 (Ki > 3 mM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY 294002, PI3-kinase inhibitor, 1MG
MW 307.3 Da, Purity >99%. A highly selective inhibitor of phosphatidylinositol 3-kinase (IC₅₀ = 1.4 μM). Selective over a range of other kinases including protein kinase C, protein kinase A, MAPK and PI4- kinase (IC₅₀ > 50 μM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Endothelin-1 (human, porcine), Vasoconstrictor peptide, 10UG
MW 2491.9 Da. Endothelin-1 (human, porcine), Vasoconstrictor peptide. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement